| Autor: |
Spiteri G; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy., Monaco MGL; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy., Caliskan G; Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy., Carta A; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.; Section of Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy., Pezzani MD; Infectious Diseases Unit, University Hospital of Verona, 37134 Verona, Italy., Lippi G; Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, 37134 Verona, Italy., Gibellini D; Section of Microbiology, Department of Diagnostics and Public Health, University of Verona, 37129 Verona, Italy., Verlato G; Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy., Porru S; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.; Section of Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy. |
| Abstrakt: |
Introduction: The anti-spike (S) IgG assay is the most widely used method to assess the immunological response to COVID-19 vaccination. Several studies showed that subjects with perivaccination infection have higher anti-S IgG titers. However, a cut-off has not yet been identified so far for distinguishing infected subjects after vaccination. This study thus evaluates the performance of the anti-S IgG assay in identifying subjects with breakthrough infections (BIs) and its potential usefulness for screening healthcare workers (HCWs). Methods: Out of 6400 HCWs of the University Hospital of Verona vaccinated with two doses of BNT162b2, 4462 never infected before subjects who had completed primary vaccination were tested for IgG anti-S 6 to 9 months after the second dose. Of these, 59 (1.3%) had a BI. The discriminant power of IgG anti-S in detecting previous breakthrough infection was tested by constructing receiver operating characteristic (ROC) curves. Results: The discriminant power for BI was rather good (area under the curve (AUC), 0.78) and increased with decreasing time elapsed between antibody titer assessment and previous SARS-CoV-2 infection. Accuracy (AUC) sensitivity increased from 0.78 (95% CI 0.70−0.85) for BI in the previous six months to 0.83 (95% CI 0.67−0.99) for those in the previous two months, and from 0.68 to 0.80, respectively. The specificity (0.86) and optimal cut-off (935 BAU/mL) remained unchanged. However, BI were rather rare (1.3%), so the positive predictive value (PPV) was low. Only 40 of the 664 HCWs with antibody titer > 935 BAU/mL had previously confirmed BI, yielding a PPV of only 6.0%. When adopting as cut-off the 90th percentile (1180 BAU/mL), PPV increased to 7.9% (35/441). Conclusions: The anti-S IgG assay displayed good sensitivity and specificity in discriminating subjects with BI, especially in recent periods. However, BIs were rare among HCWs, so that the anti-S IgG assay may have low PPV in this setting, thus limiting the usefulness of this test as a screening tool for HCWs. Further studies are needed to identify more effective markers of a previous infection in vaccinated subjects. |
